Serina Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Serina Therapeutics, Inc. (SER) reported Increase (Decrease) in Accrued Liabilities of $113.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- Serina Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$49.00K, a 117.95% decline year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $162.00K.
- Serina Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $67.00K, a 75.00% decline year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$183.00K, a 156.13% decline year-over-year.
- Serina Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$231.00K, a 157.75% decline from fiscal 2024.
- Serina Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $400.00K.
- Serina Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$140.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $113.00K 10-Q · filed 2026-08-13 | $180.00K derived: sum of 3 quarters · filed 2026-08-13 | -$3.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $162.00K 10-Q · filed 2026-05-14 | $229.00K derived: sum of 2 quarters · filed 2026-05-14 | $46.00K derived: sum of 3 quarters · filed 2026-05-14 | $319.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$116.00K derived: sum of 2 quarters · filed 2026-03-25 | $157.00K derived: sum of 3 quarters · filed 2026-08-13 | -$231.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | -$183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $90.00K derived: sum of 2 quarters · filed 2026-08-13 | -$298.00K 10-Q · filed 2025-11-13 | -$30.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $273.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$115.00K 10-Q · filed 2026-08-13 | $153.00K derived: sum of 3 quarters · filed 2026-08-13 | $479.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$388.00K 10-Q · filed 2026-05-14 | -$120.00K derived: sum of 2 quarters · filed 2026-05-14 | $206.00K derived: sum of 3 quarters · filed 2026-05-14 | -$391.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $594.00K derived: sum of 2 quarters · filed 2026-03-25 | -$3.00K derived: sum of 3 quarters · filed 2026-03-25 | $400.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$271.00K derived: sum of 2 quarters · filed 2025-11-13 | $132.00K 10-Q · filed 2025-11-13 | $54.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$194.00K 10-Q · filed 2025-08-11 | -$272.00K derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $403.00K 10-Q · filed 2025-05-08 | $325.00K derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2023-12-31 | -$78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$140.00K 10-K · filed 2025-03-24 | ||
| 2023-09-30 | -$62.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |